Pharmacy and Pharmaceutical Sciences Commons^™

A Pilot Chemical And Physical Stability Study Of Extemporaneously Compounded Levetiracetam Intravenous Solution, Chenzira D. Raphael, Fang Zhao, Susan E. Hughes, Katherine Juba

Doctoral External Publications

Levetiracetam is a commonly used antiepileptic medication for tumor-related epilepsy. However, the 100 mL intravenous (IV) infusion volume can be burdensome to imminently dying hospice patients. A reduced infusion volume would improve patient tolerability. The purpose of this study was to evaluate the stability of 1000 mg/25 mL (40 mg/mL) levetiracetam IV solution in sodium chloride 0.9%. We prepared levetiracetam 40 mg/mL IV solution and added it to polyvinyl chloride (PVC) bags, polyolefin bags, and polypropylene syringes. Triplicate samples of each product were stored at refrigeration (2–8°C) and analyzed on days 0, 1, 4, 7, and 14. Samples were subjected …

Stability Of Glutamate-Aspartate Cardioplegia Additive Solution In Polyolefin Iv Bags, Steven D. Rush, Stephanie E. Kim, Susan E. Hughes, Justine M. Gilbert, Peter P. Ciancaglini, Fang Zhao

Doctoral External Publications

Objective: Glutamate-aspartate cardioplegia additive solution (GACAS) is used to enhance myocardial preservation and left ventricular function during some cardiac surgeries. This study was designed to evaluate the stability of compounded GACAS stored in sterile polyolefin intravenous (IV) bags. The goal is to extend the default USP beyond-use date (BUD) and reduce unnecessary inventory waste.

Methods: GACAS was compounded and packaged in sterile polyolefin 250 mL IV bags. The concentration was 232 mM for each amino acid. The samples were stored under refrigeration (2°C-8°C) and analyzed at 0, 1, and 2 months. At each time point, the samples were evaluated by …

Drug-Drug Interactions Among Hepatitis C Virus (Hcv) And Human Immunodeficiency Virus (Hiv) Medications, Kirpal Kaur, Mona A. Gandhi, Judianne Slish

Doctoral External Publications

One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and mortality in HIV-HCV coinfected individuals. Optimal treatment in this patient population is critical, as coinfection has been linked to deterioration of both disease states. The objective of this review article is to highlight the current literature on drug-drug interactions between HIV and HCV treatments. The management of the treatment of coinfection patients has been covered extensively in numerous other publications.